KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Resmed (RMD) Research & Development (2016 - 2025)

Resmed's Research & Development history spans 17 years, with the latest figure at $91.0 million for Q4 2025.

  • For Q4 2025, Research & Development rose 11.79% year-over-year to $91.0 million; the TTM value through Dec 2025 reached $348.7 million, up 9.36%, while the annual FY2025 figure was $331.3 million, 7.73% up from the prior year.
  • Research & Development reached $91.0 million in Q4 2025 per RMD's latest filing, up from $87.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $91.0 million in Q4 2025 to a low of $55.9 million in Q1 2021.
  • Average Research & Development over 5 years is $73.7 million, with a median of $76.1 million recorded in 2023.
  • Peak YoY movement for Research & Development: rose 21.5% in 2023, then increased 0.83% in 2024.
  • A 5-year view of Research & Development shows it stood at $62.5 million in 2021, then rose by 11.79% to $69.9 million in 2022, then rose by 5.73% to $73.9 million in 2023, then increased by 10.14% to $81.4 million in 2024, then increased by 11.79% to $91.0 million in 2025.
  • Per Business Quant, the three most recent readings for RMD's Research & Development are $91.0 million (Q4 2025), $87.3 million (Q3 2025), and $86.4 million (Q2 2025).